EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

NAFLD/MASLD and the Gut–Liver Axis: From Pathogenesis to Treatment Options

Natalia G Vallianou iD, Dimitris Kounatidis iD, Sotiria Psallida, Nikolaos Vythoulkas-Biotis, Andreas Adamou, Tatiana Zachariadou, Sofia Kargioti, Irene Karampela iD, Maria Dalamaga iD

Metabolites · 28.06.2024 · 14 (7) · 366

DOI: 10.3390/metabo14070366 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Metabolites, online erschienen am 28.06.2024. Verfasst von Natalia G Vallianou und 8 weiteren Autor:innen. Beteiligte Einrichtung: First Department of Internal Medicine, Sismanogleio General Hospital, Sismanogliou 1 Str., 15126 Athens, Greece. Die Arbeit wurde bisher 101-mal zitiert (Crossref) und nennt 133 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Nonalcoholic fatty liver disease (NAFLD) poses an emerging threat topublic health. Nonalcoholic steatohepatitis (NASH) is reported to be the most rapidly rising cause of hepatocellular carcinoma in the western world. Recently, a new term has been proposed: metabolic dysfunction-associated steatotic liver disease (MASLD). The introduction of this new terminology has sparked a debate about the interchangeability of these terms. The pathogenesis of NAFLD/MASLD is thought to be multifactorial, involving both genetic and environmental factors. Among these factors, alterations in gut microbiota and gut dysbiosis have recently garnered significant attention. In this context, this review will further discuss the gut–liver axis, which refers to the bidirectional interaction between the human gut microbiota and the liver. Additionally, the therapeutic potential of probiotics, particularly next-generation probiotics and genetically engineered bacteria, will be explored. Moreover, the role of prebiotics, synbiotics, postbiotics, and phages as well as fecal microbiota transplantation will be analyzed. Particularly for lean patients with NAFLD/MASLD, who have limited treatment options, approaches that modify the diversity and composition of the gut microbiota may hold promise. However, due to ongoing safety concerns with approaches that modulate gut microbiota, further large-scale studies are necessary to better assess their efficacy and safety in treating NAFLD/MASLD.

Schlagwörter

Stichwörter der Autor:innen

fatty liverfecal microbiota transplantationgut dysbiosisgut microbiotametabolic dysfunction-associated steatotic liver diseasenonalcoholic fatty liver diseasephagepostbioticsprebioticsprobiotics

Autor:innen und Institutionen

  • First Department of Internal Medicine, Sismanogleio General Hospital, Sismanogliou 1 Str., 15126 Athens, Greece.
  • Department of Internal Medicine, Hippokration General Hospital, 114 Vassilissis Sofias Str., 11527 Athens, Greece.
  • Department of Microbiology, "KAT" General Hospital of Attica, 14561 Athens, Greece.
  • Second Department of Critical Care, Attikon University Hospital, 1 Rimini Str., 12462 Athens, Greece.
  • Department of Biological Chemistry, National and Kapodistrian University of Athens, 75 Mikras Asias Str., 11527 Athens, Greece.

ORCID-Profile: Natalia G Vallianou, Dimitris Kounatidis, Irene Karampela, Maria Dalamaga

Zitieren

APA

Vallianou, N. G., Kounatidis, D., Psallida, S., Vythoulkas-Biotis, N., Adamou, A., Zachariadou, T., Kargioti, S., Karampela, I., & Dalamaga, M. (2024). NAFLD/MASLD and the Gut–Liver Axis: From Pathogenesis to Treatment Options. Metabolites, 14(7), 366. https://doi.org/10.3390/metabo14070366

Vancouver

Vallianou NG, Kounatidis D, Psallida S, Vythoulkas-Biotis N, Adamou A, Zachariadou T, et al. NAFLD/MASLD and the Gut–Liver Axis: From Pathogenesis to Treatment Options. Metabolites. 2024;14(7):366. doi:10.3390/metabo14070366

BibTeX
@article{Vallianou2024,
  author = {Vallianou, Natalia G and Kounatidis, Dimitris and Psallida, Sotiria and Vythoulkas-Biotis, Nikolaos and Adamou, Andreas and Zachariadou, Tatiana and Kargioti, Sofia and Karampela, Irene and Dalamaga, Maria},
  title = {NAFLD/MASLD and the Gut–Liver Axis: From Pathogenesis to Treatment Options},
  journal = {Metabolites},
  year = {2024},
  volume = {14},
  number = {7},
  pages = {366},
  doi = {10.3390/metabo14070366}
}
Kostenlos starten →